Table 1.
The polymorphisms and level of dopamine receptors in cancers.
| Type of cancers | Relationship between dopamine receptors and cancer | References |
|---|---|---|
| breast cancer | DRD1↑, DRD2↑, DRD3↑, DRD4↑ | 29 |
| cervical cancer | DRD2↑ | 39 |
| cholangiocarcinoma | Mz-chA-1: DRD1↑, DRD2↑, DRD3↑, DRD4↓,DRD5↑ | 64 |
| HuCCT-1: DRD1↓, DRD2↑, DRD4↓,DRD5↓ | 64 | |
| SG231: DRD2↓, DRD3↓, DRD4↓,DRD5↓ | 64 | |
| CCLP-1: DRD1↓, DRD2↑, DRD3↓, DRD4↓,DRD5↓ | 64 | |
| colorectal cancer | DRD2↓;DRD2 polymorphisms -141Cdel, 957T>C, 1412A>G are associate with colorectal cancer. | 123 |
| HCT116: DRD1↑, DRD2↑,DRD5↑ | 84 | |
| HT29: DRD1↑, DRD2↑,DRD5↑ | 84 | |
| The DRD2 rs1799732 CT, rs1800497 TT are associated increase cancer risk. | 24 | |
| corticotroph adenomas | DRD2↑ | 124 |
| gastric cancer | DRD2↑ | 26 |
| glioblastoma | DRD2↑ | 28 |
| U251: DRD1↑, DRD2↑,DRD5↑ | 84 | |
| hepatic carcinoma | DRD1↓, DRD5↑ | 94 |
| Hep3B: DRD1↑, DRD5↑ | 84 | |
| lung cancer | DRD2↑ | 125 |
| neuroblastoma | SKNAH: DRD1↑, DRD2↑, DRD4↑,DRD5↑ | 84 |
| neuroendocrine | DRD2↑ | 126 |
| DRD2↑ | 27 | |
| DRD2↑ | 127 | |
| non-small cell lung cancer | DRD2 polymorphisms -141Cdel, 3208G>T; DRD4 -521C>T are associated with increase NSCLC risk. | 25 |
| ovarian | DRD2↑ | 53 |
| pancreatic cancer | DRD2↑ | 40 |
| pheochromocytoma | DRD2↑ | 128 |
| DRD2↑ | 129 | |
| pituitary adenoma | DRD2↑ | 130 |
| small cell lung cancer | DRD2↑, DRD4↑,DRD5↑ | 70 |